![Docetaxel [Taxotere] – (Chemotherapy for Prostate Cancer)](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E)
Introduction
Docetaxel, sold under the trade name Taxotere, is a chemotherapy medication widely used in the treatment of advanced or metastatic prostate cancer. Often combined with androgen deprivation therapy (ADT), it helps to slow tumor progression and improve survival rates in patients with hormone-sensitive or castration-resistant prostate cancer.
Purpose
- Treats metastatic hormone-sensitive prostate cancer (mHSPC).
- Effective in castration-resistant prostate cancer (mCRPC).
- Reduces tumor size and improves overall survival in advanced stages of prostate cancer.
How It Works
Docetaxel interferes with microtubule function during cell division, preventing cancer cells from replicating and leading to their death. Its mechanism makes it particularly effective against rapidly dividing cancer cells.
Usage
- Administered via intravenous (IV) infusion, typically every three weeks.
- Often given in cycles, with a standard course consisting of 6-10 cycles.
- Pre-medication with steroids like dexamethasone is common to reduce side effects.
Considerations
- Common side effects include fatigue, hair loss, nausea, and peripheral neuropathy.
- Serious risks include low white blood cell counts (neutropenia), infections, and fluid retention.
- Requires close monitoring by a healthcare team to manage side effects and ensure safety.
At Crossroads Urology
At Crossroads Urology, Docetaxel is a critical component of our advanced prostate cancer treatment strategy. We work closely with oncology specialists to provide seamless care, ensuring patients receive the full benefit of this therapy while minimizing side effects.
Conclusion
Docetaxel [Taxotere] offers proven benefits for patients with advanced or metastatic prostate cancer, helping to extend survival and improve quality of life. Contact Crossroads Urology today to learn more about this treatment and how it fits into a comprehensive cancer care plan.
